TOP2B
ENSG00000077097
Target class
Enzyme
Chromosome
3
Approved drugs
5
Clinical candidates (approved and in development)
10
- Approved drugs
- 5
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 10
- Chemical probe available
- No
- Target name
- TOP2B
- Gene name
- DNA topoisomerase II beta
- Gene symbol
- TOP2B
- Protein name
- DNA topoisomerase 2-beta (EC 5.6.2.2) (DNA topoisomerase II, beta isozyme)
- top2beta
- TOPIIB
- Gene biotype
- Protein coding
- Gene family
- Topoisomerases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 134.38
- Tissue specificity (Gini)
- 0.233
- Tissue specificity (tau)
- 0.595
- KEGG gene identifiers
- hsa:7155
- Reactome pathways
- R-HSA-4615885
- Protein interaction confidence
- 0.804867
- Protein interaction partners
- 15
- End position
- 25664973
- Start position
- 25597978
- Chromosome
- 3
- Strand
- Reverse
- Nucleus, nucleolus . Nucleus, nucleoplasm . Nucleus .
- Nucleoplasm
- PubMed 8299728
- PubMed 9155056
- PubMed 19690332
- Tissue specificity (tau)
- 0.595244
- Expression inequality (Gini)
- 0.23288
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 134.38
- Brain - Cerebellum
- 106.57
- Cells - EBV-transformed lymphocytes
- 93.15
- Uterus
- 92.55
- Cervix - Endocervix
- 88.5
Expression in transcripts per million
- Brain - Cerebellar Hemisphere134.38
- Brain - Cerebellum106.57
- Cells - EBV-transformed lymphocytes93.15
- Uterus92.55
- Cervix - Endocervix88.5
- Ovary85.75
- Nerve - Tibial80.86
- Artery - Tibial79.98
- Bladder79.37
- Fallopian Tube76.91
- Cells - Cultured fibroblasts75.06
- Vagina75.06
- Thyroid73.11
- Colon - Sigmoid72.06
- Cervix - Ectocervix71.95
- Esophagus - Gastroesophageal Junction67.38
- Artery - Aorta66.4
- Esophagus - Muscularis65.98
- Prostate62.36
- Skin - Sun Exposed (Lower leg)60.55
- Skin - Not Sun Exposed (Suprapubic)60.33
- Artery - Coronary60.26
- Lung59.54
- Spleen56.49
- Breast - Mammary Tissue56.46
And 29 more, listed on the interactive page.
- GO:0006265
- GO:0030183
- GO:0045870
- GO:0000792
- GO:0005634
- GO:0005654
- GO:0005730
- GO:0005829
- GO:0003682
- GO:0003918
- GO:0005515
Related records
Trials (1,512)
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma
- 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
- A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
- A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma
- A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma
- A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages
- A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
- A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines
- A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL
- A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
- A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.
- A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
- A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)
- A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas
- A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Drugs (12)
- Aclarubicin
- Amsacrine DNA topoisomerase II inhibitor
- Becatecarin DNA topoisomerase II inhibitor
- Berubicin DNA topoisomerase II inhibitor
- Berubicin hydrochloride DNA topoisomerase II inhibitor
- C-1311 DNA topoisomerase II inhibitor
- Dexrazoxane DNA topoisomerase II inhibitor
- Dexrazoxane hydrochloride DNA topoisomerase II inhibitor
- Etoposide DNA topoisomerase II inhibitor
- Pazufloxacin DNA topoisomerase II inhibitor
- Teniposide DNA topoisomerase II inhibitor
- Vosaroxin DNA topoisomerase II inhibitor